Human T cell responses against melanoma.

By T. Boon, P. Coulie, B. J. Van den Eynde, P. van der Bruggen. Annual Review of Immunology, 2006

666 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/aec32b4b5f4ce9904a8e9787959990313189b8fb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008, background): “Indeed, because some molecularly defined cancer antigens are nonmutated differentiation proteins expressed in normal tissues (29), tumor immunity and autoreactivity may be tightly associated in particular contexts.”
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting (2012, neutral): “Tumour-specific mutant proteins presented on mouse or human MHC class I molecules are known to represent one class of tumour-specific antigens for CD8 + T cells 18,19 .”
Adoptive immunotherapy for cancer: building on success (2006, background): “CD8 + T cells have been identified as potent effectors of the adaptive antitumour immune respons”
Imaging in the era of molecular oncology (2008, background): “Antitumour cytotoxic T cells (CTLs) that recognize short antigenic peptides presented by tumour cells can kill their targets in an antigen-dependent and contact-dependent manner by releasing preformed cytotoxic granules or by generating potent inflammatory responses through the secretion of cytokine”
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients (2010, background): “, 1988), CGAs represent strictly tumor-specific T cell targets (Boon et al., 2006).”
T Cell Dysfunction in Cancer (2018, background): “While the presence of tumorinfiltrating lymphocytes (TILs), and in particular CD8+ T cells, is a positive prognostic marker in multiple solid tumors (Fridman et al., 2012), these cells fail to effectively eliminate cancer cells (Boon et al., 2006).”
Challenges in liver cancer and possible treatment approaches (2019, background): “However, this mechanism may be ineffective due to the capacity of malignancies to evade these functions [12, 13].”
Integrative Clinical Genomics of Metastatic Cancer (2017, neutral): “9b), including kidney cancer 31,32 , lung cancer 33 , and melanoma 34 , remained infiltrated at metastatic sites.”
Cancer immunotherapy via dendritic cells (2012, neutral): “Candidate tumour antigens include unique (mutated) antigens and shared non-mutated self-antigen”
Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “Naive CD8 T cells differentiate into CTLs in lymphoid organs upon encounter with DCs presenting tumor-derived peptides (Bousso and Robey, 2003) (Figure 2) in the context of costimulation through CD80, CD70, and 4-1BB (Shuford et al.”